country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P99396A

Copy Link Print Information

Spesolimab (LALA)

Name: Spesolimab (LALA)
Brand: MedChemExpress
SKU: HY-P99396A
Availability: PreOrder

(Synonyms: MAB92 (LALA); BI 655130 (LALA))

Spesolimab (MAB92; BI 655130) (LALA) is a humanized IgG1k antibody against IL-36R with a K_d value of 20 pM. Spesolimab (LALA) selectively blocks IL-36R signaling without inhibiting related interleukin pathways. Spesolimab (LALA) lacks functional cross-reactivity with non-human IL-36R and exhibits species-specific binding to human IL-36R, with reduced affinity for mouse, rat, hamster, minipig, and non-human primate IL-36R. Spesolimab (LALA) has L234A and L235A mutations introduced into the Fc region, designed to reduce antibody binding to FcγR and C1q, thereby attenuating/eliminating the ADCC and CDC effector functions of the antibody. Spesolimab (LALA) can be used for research on generalized pustular psoriasis (GPP).

For research use only. We do not sell to patients.

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (276 KB)

Spesolimab (LALA) Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

IL-1RL2/IL-36R

All Interleukin Related Isoforms :

In Vitro

Cytokines & ChemokinesInnate ImmunityCytokines and Chemokines

Cytokines & Chemokines

Innate Immunity

Spesolimab (LALA) neutralizes IL-36α/β/γ-induced NF-κB activation and IL-8 production in primary human keratinocytes^[1].
Spesolimab (LALA) selectively blocks IL-36-induced NF-κB activation in NCI/ADR-RES ovarian epithelial cells but does not inhibit IL-1β-induced NF-κB activation or cytokine release in IL-36R knockout NCI/ADR-RES cells or human primary cells^[1].

Cytokines and Chemokines

Spesolimab (LALA) binds hIL-36R with high affinity (K_D = 24 pM; SPR K_D = 20 pM) at a D1-D2 site distinct from the IL-36α/β/γ and IL-36Ra binding sites^[1].
Spesolimab (LALA) binds human IL-36R with a K_D of 0.020 nM and has >2000-fold reduced affinity for the tested nonhuman IL-36R orthologs^[2].

Innate Immunity

Cytokines & Chemokines

Spesolimab (LALA) inhibits IL-36R-driven NF-κB activation in primary intestinal myofibroblasts and primary dermal fibroblasts with IC₉₀ values of 3.2 nM and 9.9 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Imiquimod-Induced Psoriasiform Dermatitis

Parmacokinetics

Species	Dose	Route	Clearance (CL)	V	T_1/2
Cynomolgus Monkey^[2]	0.3 mg/kg	i.v.	0.22 mL/h/kg	83.0 mL/kg	284 h
Cynomolgus Monkey^[2]	1.5 mg/kg	i.v.	0.19 mL/h/kg	65.2 mL/kg	288 h
Cynomolgus Monkey^[2]	10 mg/kg	i.v.	0.17 mL/h/kg	75.5 mL/kg	349 h

Chemical Information

SMILES

[Spesolimab (LALA)]
Synonyms

MAB92 (LALA); BI 655130 (LALA)
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Inhibitory Antibodies User Guide (603 KB)

References

[1]. Morita A, et al. Spesolimab, the first-in-class anti-IL-36R antibody: From bench to clinic. J Dermatol. 2024 Nov;51(11):1379-1391. [Content Brief]

[2]. Ahlberg J, et al. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5). mAbs. 2019 Jul;11(5):956-964. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote